-
1.发明申请GALECTIN-3 INHIBITOR (GAL-3M) IS ASSOCIATED WITH ADDITIVE ANTI-MYELOMA AND ANTI-SOLID TUMOR EFFECTS, DECREASED OSTEOCLASTOGENESIS AND ORGAN PROTECTION WHEN USED IN COMBINATION WITH PROTEASOME INHIBITORS 审中-公开GALECTIN-3抑制剂（GAL-3M）与添加抗血清和抗固体肿瘤效应有关，当与抗抑郁药组合使用时，减少了OSTEOCLASTOGENESISISIS和ORGAN保护
公开(公告)号：WO2015117127A1
公开(公告)日：2015-08-06
申请号：PCT/US2015/014246
申请日：2015-02-03
Applicant: TEXAS TECH UNIVERSITY SYSTEM
Inventor： CHIRIVA-INTERNATI, Maurizio , FIGUEROA, Jose, A. , COBOS, Everardo
CPC classification number: C07K14/4726 , A61K31/145 , A61K31/27 , A61K31/336 , A61K31/353 , A61K31/4015 , A61K31/407 , A61K31/427 , A61K31/5377 , A61K31/69 , A61K31/713 , A61K38/05 , A61K38/06 , A61K38/07 , A61K38/1732 , A61K45/06 , G01N33/5011 , A61K2300/00 , A61K31/365
Abstract: The present invention includes a method for the treatment of myeloma comprising identifying a patient with myeloma and administering to the patient a synergistic, effective amount of a truncated, dominant negative form of Galectin-3 and a proteasome inhibitor.
Abstract translation: 本发明包括用于治疗骨髓瘤的方法，包括鉴定患有骨髓瘤的患者，并向患者施用协同的有效量的半抗原，显性失活形式的Galectin-3和蛋白酶体抑制剂。
-
公开(公告)号：WO2015085207A1
公开(公告)日：2015-06-11
申请号：PCT/US2014/068855
申请日：2014-12-05
Applicant: TEXAS TECH UNIVERSITY SYSTEM
Inventor： CHIRIVA-INTERNATI, Maurizio , FIGUEROA, Jose, A. , COBOS, Everardo
CPC classification number: A61K38/1732 , A61K31/337 , A61K48/00 , C07K14/4726 , G01N33/57449 , G01N2500/10 , A61K2300/00
Abstract: The present invention includes a method for the treatment of an advanced ovarian cancer, comprising: identifying a patient with advanced ovarian cancer; and administering to the patient an effective amount of truncated, dominant negative form of Galectin-3 sufficient to reduce the advanced ovarian cancer. In certain aspects, the truncated, dominant negative form of Galectin-3 is provided in an amount sufficient to reduce at least one of growth, motility, invasion, angiogenesis, or prevents Akt/NF-ĸΒ activation of the ovarian cancer.
Abstract translation: 本发明包括一种治疗晚期卵巢癌的方法，包括：鉴定晚期卵巢癌患者; 并向患者施用足够减少晚期卵巢癌的有效量的截短，显性阴性形式的Galectin-3。 在某些方面，提供半数优势阴性形式的半乳凝素-3以足以减少生长，运动，侵袭，血管发生或抑制卵巢癌的Akt / NF-κB活化中的至少一种的量。
-
3.发明申请CANCER TESTIS ANTIGEN SPERM PROTEIN 17 AS A TARGET FOR BREAST CANCER IMMUNOTHERAPY AND DIAGNOSIS 审中-公开癌症TESTIS抗原蛋白17作为乳腺癌的手段免疫和诊断
公开(公告)号：WO2016019298A2
公开(公告)日：2016-02-04
申请号：PCT/US2015/043214
申请日：2015-07-31
Applicant: TEXAS TECH UNIVERSITY SYSTEM
Inventor： CHIRIVA-INTERNATI, Maurizio
IPC: A61K39/395 , A61K39/39 , A61K48/00 , A61P35/00
CPC classification number: A61K39/0011 , A61K31/138 , A61K31/555 , A61K45/06 , A61K2039/5154 , A61K2039/5158 , G01N33/57415 , G01N2333/705 , G01N2800/52 , A61K2300/00
-
4.发明申请
公开(公告)号：WO2014127006A1
公开(公告)日：2014-08-21
申请号：PCT/US2014/016032
申请日：2014-02-12
Applicant: TEXAS TECH UNIVERSITY SYSTEM
Inventor： CHIRIVA-INTERNATI, Maurizio
IPC: A61K39/395 , A61K35/12 , A61P35/00
CPC classification number: A61K39/0011 , A61K35/15 , A61K2039/5154 , A61K2039/572 , C07K14/47 , C07K14/705 , C07K16/3023 , C12N9/12 , G01N33/57423 , G01N33/57488 , G01N2333/47 , G01N2333/705 , G01N2333/912
Abstract: The present invention includes compositions and methods for the diagnosis and treatment of lung cancer with a recombinant tumor-associated antigen loaded antigen presenting cell that generates a cytotoxic T lymphocyte specific immune response to at least one of SP17, AKAP-4, or PTTGl expressed by one or more lung cancer cells.
Abstract translation: 本发明包括用重组肿瘤相关抗原负载的抗原呈递细胞诊断和治疗肺癌的组合物和方法，其产生对SP17，AKAP-4或PTTG1中的至少一种的细胞毒性T淋巴细胞特异性免疫应答，由SP17，AKAP-4或PTTG1中的至少一种表达 一个或多个肺癌细胞。
-
-
-
Search Results
4
records
(took 0.018 seconds)
